Will QuidelOrtho stock go up?

According to Danelfin AI, QuidelOrtho has today an AI Score of 2/10 (Strong Sell rating), because its probability of beating the market in 3 months (42.06%) is -8.76% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for QuidelOrtho stock?

The QuidelOrtho target price is $24.58 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold QuidelOrtho stock right now?

QuidelOrtho has today a Strong Sell rating (AI Score 2/10), according to Danelfin AI. Its probability of beating the market in 3 months (42.06%) is -8.76% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether QuidelOrtho stock is a good buy .

Is QuidelOrtho undervalued right now?

Based on analysts, the average price target upside for QuidelOrtho is +35.03% (1Y). According to Danelfin AI, QuidelOrtho has today an AI Score of 2/10 (Strong Sell Rating).

What was the price range of QuidelOrtho stock over the past 12 months?

The QuidelOrtho stock price range over the past 12 months has been $9.96 - $35.38.

What is going on with QuidelOrtho stock in the last 3 months?

The QuidelOrtho stock performance in the last quarter has been +10.77%.

Does QuidelOrtho offer dividend payments?

No, QuidelOrtho does not currently pay dividends.

What is the current market capitalization of QuidelOrtho?

QuidelOrtho's market cap is $1.24B, as of 2026-07-02 08:00.

When is the next QDEL earnings report date?

QDEL will publish its next earnings report on 2026-05-05.

QuidelOrtho Corp (QDEL) AI Stock Analysis

Advanced Chart

Custom range

Jul 2, 2025

→

Jul 2, 2026

Custom range

Jul 2, 2025

→

Jul 2, 2026

QDEL AI-Powered Stock Analysis

AI Score Explanation

AI Score

Strong Sell

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, QuidelOrtho Corp today receives an AI Score of 2/10, which translates to a Sell rating. The stock has a 43% probability of outperforming the market in the next 3 months, which is 8% lower than the average probability of any stock (51%). The top positive contributors include Net Property, Plant & Equipment (Net PP&E) in the top 30% (impact +0.91%), Performance (YTD) in the bottom 20% (impact +0.78%), and Earnings Countdown in the bottom 20% (impact +0.62%). On the detractor side, the Industry (GICS) being Health Care Equipment & Supplies has the strongest negative impact (-2.58%), followed by Basic EPS Consolidated in the bottom 10% (-1.60%), and the Fundamentals Impact (Long Tail) (-1.53%). Notable data points include a Fear & Greed Index of 31, indicating extreme fear, which detracts -1.01% from the probability. The company has a negative Operating Profit Margin of -5.13% (bottom 40%), and Tangible Shareholders' Equity is negative at -$668.8M (bottom 10%), both weighing on the outlook. However, Net PP&E of $1,339.3M (top 30%) provides a positive anchor. Overall, the preponderance of negative signals—especially the industry headwind, poor earnings per share, and weak profitability—outweigh the few positive factors, resulting in a low AI Score and a Sell rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Size & Liquidity+0.39%
Company size and trading liquidity

Sentiment-3.98%
How analysts and the market view the stock
Growth-1.60%
Expected pace of revenue and earnings expansion
Momentum-1.14%
Direction and strength of recent price movements
Valuation-1.13%
How the stock is priced relative to its fundamentals
Volatility-0.85%
How much the stock price tends to fluctuate
Profitability-0.44%
Profitability and operating efficiency metrics

QDEL probability advantage of beating the market (3M):

-8.76%

AI Score

Strong Sell

QuidelOrtho (QDEL) has an AI Score of 2/10 (Strong Sell) because, according to an overall analysis, it has a probability advantage of -8.76% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of QDEL (42.06%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
QDEL probability advantage of beating the market (3M)-8.76%
QDEL probability of beating the market (3M)42.06%

QDEL probability advantage of beating the market (3M): -8.76%

The AI-powered overall analysis of QuidelOrtho (QDEL) is based on the 25 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of QDEL:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Sentiment	Industry (GICS)	Health Care Equipment & Supplies	N/A	-2.58%
Fundamental	Basic EPS Consolidated	-1.35	N/A	-1.60%
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	-1.53%
Technical	Chart Pattern (504d)	figure_92	N/A	-1.41%
Technical	Technicals Impact (Long Tail)	-	N/A	-1.34%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-1.01%
Sentiment	Sentiment Impact (Long Tail)	-	N/A	-1.00%
Fundamental	Net Property, Plant & Equipment (Net PP&E)	1.34K		+0.91%
Technical	Performance (YTD)	-0.36%		+0.78%
Sentiment	Earnings Countdown	-52		+0.62%
Fundamental	Upgrade to unlock			-0.51%
Technical	Upgrade to unlock			-0.49%
Technical	Upgrade to unlock			+0.45%
Fundamental	Upgrade to unlock			-0.44%
Fundamental	Upgrade to unlock			+0.44%

Rest of Alpha Signals: +0.80%

QDEL probability advantage of beating the market (3M)Total:-8.76%
QDEL AI Score

Significant changes Vs previous day

QDEL Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$18.20
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

QDEL Proven Sell Signal & Price Forecast

This is the price chart for QDEL from January 1, 2026 until today. The chart indicates, in red, the 63 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

QDEL Average Past Performance & Loss Rate

Three months after its 264 Sell signals since June 2026, QDEL had an average performance of xxxxxxx and a xxxxxx Loss rate (negative performance).

264 Past QDEL Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-6.77%
Average Alpha				-31.98%
Loss Rate (% Negative Perf.)				72.06%
% Negative Alpha				90.44%

QDEL Past Sell Signals Performance

Performance and alpha after 1, 3, 6 months, and 1 year, for each of the 247 days that QDEL was rated a Strong Sell/Sell (AI Score 1 to 3) since June 2026.

Date	Perf. 1M	Perf. 3M	Perf. 6M	Perf. 1Y	Alpha. 1M	Alpha. 3M	Alpha. 6M	Alpha. 1Y
2018-12-19	+5.87%	+29.93%	+20.86%	+49.23%	+1.26%	+18.79%	+3.85%	+21.51%
2019-02-26				-	-	-	-	-
-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-
Showing 1 to 10 of 247 days 1 2 3 4 5 ... 25
-	-	-	-	-	-	-	-	-

Date	AI Score	Perf. 1M	Perf. 3M	Perf. 6M	Perf. 1Y	Alpha. 1M	Alpha. 3M	Alpha. 6M	Alpha. 1Y

QDEL Frequently Asked Questions

Will QuidelOrtho stock go up?
According to Danelfin AI, QuidelOrtho has today an AI Score of 2/10 (Strong Sell rating), because its probability of beating the market in 3 months (42.06%) is -8.76% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for QuidelOrtho stock?
Is it a good time to buy, sell, or hold QuidelOrtho stock right now?
Is QuidelOrtho undervalued right now?
What was the price range of QuidelOrtho stock over the past 12 months?
What is going on with QuidelOrtho stock in the last 3 months?
Does QuidelOrtho offer dividend payments?
What is the current market capitalization of QuidelOrtho?
When is the next QDEL earnings report date?

QuidelOrtho Corp Company Profile

QuidelOrtho Corporation is a provider of diagnostic testing solutions. Split into four primary business units, namely Labs, Transfusion Medicine, Point-of-Care and Molecular Diagnostics, QuidelOrtho brings its services to diverse medical settings.

The Labs division is dedicated to providing clinical chemistry laboratory instruments and tests that measure chemical changes in bodily fluids crucial for patient evaluation and management. The unit also delivers immunoassay laboratory instruments and tests to follow the activity of proteins as they function as antigens spreading disease or antibodies responding to disease. Additionally, it offers a broad spectrum of diagnostic tools focused on monitoring the progression of various diseases.

Moving on to their Transfusion Medicine division, we see it specializing in immunohematology equipment and tests for blood typing - an essential element ensuring patient-donor compatibility during blood transfusions. Furthermore, it conducts donor screening assessments used to screen blood and plasma donations for potential infectious diseases.

Next is the Point-of-Care division which utilizes specialized instruments and tests to produce rapid results across multiple care settings. This allows for swift decision-making within time-sensitive care environments.

Lastly is Molecular Diagnostics which features polymerase chain reaction thermocyclers, amplification systems, plus sample-to-result molecular equipment and tests that power syndromic diagnosis of infectious diseases.These offer precise insights at a molecular level for improved treatment outcomes.

QuidelOrtho extends its offerings by selling products directly through their dedicated sales force or working with distributors who cater professional uses at hospitals, clinics - be it urgent care or retail ones -, academic establishments, pharmacies, wellness screening centres along with blood banks and donor centres. They also make their solutions available for individual non-professional use and over-the-counter sales.

Geographically spanning North America, Europe, Middle East & Africa alongside China among other international markets - this corporation enjoys global presence.With roots traced back since 1979,this company now operates from its head office located in San Diego, California.

Sector:Health Care
Country:United States
Industry:Health Care Equipment & Supplies
Address:9975 Summers Ridge Road, San Diego
Employees:6,500
Website:quidelortho.com

Pros

Recurring revenue from diagnostic instrument installed base

High switching costs for integrated laboratory systems

Regulatory barriers to entry in diagnostic markets

Broad product portfolio across diagnostic modalities

Structural demand growth from global aging population

Cons

Intense competition across diagnostic product segments

Pricing pressure from healthcare reimbursement policies

Technology disruption risk from novel diagnostic platforms

Capital intensity for research and development of assays

Revenue exposure to infectious disease demand cyclicality

Pros

Cons

Company

AI Score

Compare

DGXQuest Diagnostics Inc

OSUROraSure Technologies Inc

TRIBTrinity Biotech PLC

BLLNBillionToOne Inc

Company

AI Score

Compare

QDEL Top 10 Industry Stocks

Health Care Equipment & Supplies

	Company	AI Score	Compare
1	PODDInsulet Corp
2	UTMDUtah Medical Products Inc
3	PHGKoninklijke Philips NV
4	ALCAlcon AG
5	TMDXTransmedics Group Inc
6	CVRXCVRx Inc
7	GUTSFractyl Health Inc
8	XTNTXtant Medical Holdings Inc
9	ESTAEstablishment Labs Holdings Inc
10	INMDInmode Ltd

	Company	AI Score	Compare

QDEL Top 10 Sector Stocks

Health Care

	Company	AI Score	Compare
1	COGTCogent Biosciences Inc
2	IMNMImmunome Inc
3	VRDNViridian Therapeutics Inc
4	ZYMEZymeworks Inc
5	LBRXLB Pharmaceuticals Inc
6	PAHCPhibro Animal Health Corp
7	CGONCG Oncology Inc
8	EBSEmergent BioSolutions Inc
9	ACRVAcrivon Therapeutics Inc
10	RNAAvidity Biosciences Inc

	Company	AI Score	Compare

QDEL Stock AI Analysis